AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31340094 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (8 mg per day in a continuous regimen)
Number of subjects: 99
Study 30254362 — intervention group
Group type: EXPERIMENTAL
Intervention: LA Health intervention
Number of subjects: 0
Study 27239035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet (FMD)
Number of subjects: 100
Study 24871380 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 60 mJ
Number of subjects: 64
Study 24871380 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 100 mJ
Number of subjects: 64
Study 24871380 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 160 mJ
Number of subjects: 64
Study 24871380 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 250 mJ
Number of subjects: 64
Study 24871380 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic treatment
Number of subjects: 64
Study 22342411 — intervention group
Group type: EXPERIMENTAL
Intervention: ThuLEP (70 W)
Number of subjects: 133
Study 22342411 — intervention group
Group type: COMPARATOR
Intervention: HoLEP (90 W)
Number of subjects: 133
Study 20819082 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 2052
Study 20819082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 2052
Study 20819082 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 2052
Study 20819082 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 2052
Study 17362556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum beta-carotene concentrations
Number of subjects: 400
Study 16379601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil + HAART
Number of subjects: 6
Study 16379601 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 6
Study 12184481 — intervention group
Group type: EXPERIMENTAL
Intervention: Displayed emotion
Number of subjects: 132
Study 12184481 — intervention group
Group type: EXPERIMENTAL
Intervention: High specificity speech
Number of subjects: 132
Study 10459959 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg twice daily until labour, 600 mg at beginning of labour, and 300 mg twice daily for 7 days post partum)
Number of subjects: 421
Study 10459959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 7639221 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension 2 g BID
Number of subjects: 184
Study 7639221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 2696630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone containing multi-drug chemotherapy
Number of subjects: 182
Study 2696630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone, methotrexate and 5-fluorouracil
Number of subjects: 182
Study 2696630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, mitoxantrone, vincristine and prednisone
Number of subjects: 182
Study 2696630 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT, mitoxantrone, mitomycin C
Number of subjects: 182
Study 2696630 — intervention group
Group type: EXPERIMENTAL
Intervention: Other malignancies treatment
Number of subjects: 182
Study 2696630 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin or epirubicin combined with other drugs (control)
Number of subjects: 182
Study 46962 — intervention group
Group type: EXPERIMENTAL
Intervention: Kveim test material
Number of subjects: 81
Study 30876453 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician consultation
Number of subjects: 400
Study 30876453 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting time
Number of subjects: 400
Study 30876453 — intervention group
Group type: EXPERIMENTAL
Intervention: Total service quality score
Number of subjects: 400
Study 30876453 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient services assessment
Number of subjects: 400
Study 30876453 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive perception of service quality
Number of subjects: 400
Study 28683228 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 2255
Study 28683228 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 2255
Study 26311628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13600
Study 26311628 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13600
Study 23560258 — intervention group
Group type: EXPERIMENTAL
Intervention: XPB
Number of subjects: 120
Study 23560258 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX prior to XPB
Number of subjects: 120
Study 23560258 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN
Number of subjects: 120
Study 23560258 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX prior to XEN
Number of subjects: 120
Study 23560258 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 20702754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for 8 days
Number of subjects: 2
Study 20702754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily for 6 days
Number of subjects: 2
Study 19327379 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced life functioning message
Number of subjects: 94
Study 19327379 — intervention group
Group type: COMPARATOR
Intervention: Enhanced physical health message
Number of subjects: 94
Study 16700666 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B (NBUVB) alone
Number of subjects: 40
Study 16700666 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B (NBUVB) plus 0.05% topical calcipotriol ointment
Number of subjects: 40
Study 16700666 — intervention group
Group type: COMPARATOR
Intervention: NBUVB alone
Number of subjects: 40
Study 14715387 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine 1 mg/ml
Number of subjects: 265
Study 14715387 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine 1 mg/ml plus naloxone 0.6 microg/ml
Number of subjects: 265
Study 11882754 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 300
Study 11882754 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 300
Study 9669007 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg granisetron (Group G)
Number of subjects: 150
Study 9669007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol (Group D)
Number of subjects: 150
Study 9669007 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg granisetron plus 1.25 mg droperidol (Group GD)
Number of subjects: 150
Study 7636054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 12
Study 7636054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 12
Study 7636054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 12
Study 7636054 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 12
Study 7636054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg + Albuterol
Number of subjects: 12
Study 7636054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg + Albuterol
Number of subjects: 12
Study 7636054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg + Albuterol
Number of subjects: 12
Study 7636054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2794193 — intervention group
Group type: EXPERIMENTAL
Intervention: CAI (Computer-Assisted Instruction)
Number of subjects: 76
Study 2794193 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 76
Study 322905 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin (conjugated equine oestrogens)
Number of subjects: 125
Study 322905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 30482933 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 22
Study 30482933 — intervention group
Group type: COMPARATOR
Intervention: Acipimox
Number of subjects: 22
Study 30482933 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-502-3p overexpression
Number of subjects: 22
Study 28238711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2‐90)
Number of subjects: 13199
Study 28238711 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2‐90)
Number of subjects: 13199
Study 28238711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13199
Study 28238711 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13199
Study 26394188 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS)
Number of subjects: 4317
Study 26394188 — intervention group
Group type: EXPERIMENTAL
Intervention: Refinement of previously reported region
Number of subjects: 4317
Study 24088368 — intervention group
Group type: COMPARATOR
Intervention: Intensive Insulin Therapy (IIT) protocol presumed if median Glu₁ <6.44 mmol/L
Number of subjects: 176505
Study 24088368 — intervention group
Group type: COMPARATOR
Intervention: Control arm of NICE‐SUGAR trial
Number of subjects: 176505
Study 24088368 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 176505
Study 22069132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy with medication
Number of subjects: 50
Study 22069132 — intervention group
Group type: COMPARATOR
Intervention: Medication (tricyclic antidepressants or selective serotonin reuptake inhibitors)
Number of subjects: 50
Study 19726448 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole combined with norethisterone acetate
Number of subjects: 82
Study 19726448 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone acetate alone
Number of subjects: 82
Study 17698578 — intervention group
Group type: EXPERIMENTAL
Intervention: audio computer-assisted self-interviewing
Number of subjects: 104
Study 17698578 — intervention group
Group type: EXPERIMENTAL
Intervention: face-to-face interview with study staff
Number of subjects: 104
Study 17698578 — intervention group
Group type: EXPERIMENTAL
Intervention: self-administered paper-and-pencil questionnaire
Number of subjects: 104
Study 17698578 — intervention group
Group type: EXPERIMENTAL
Intervention: interview by study staff about adherence within the previous 24 hours
Number of subjects: 104
Study 15328251 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian extract (1000 mg nightly for 14 days)
Number of subjects: 12
Study 11432623 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose platinum (cisplatin and carboplatin)
Number of subjects: 280
Study 11432623 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 280
Study 9492500 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration sevoflurane (2.0% for 60 sec before and after pause)
Number of subjects: 0
Study 9492500 — intervention group
Group type: COMPARATOR
Intervention: Conventional sevoflurane (1.0%)
Number of subjects: 0
Study 9492500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow sevoflurane (0.5 l.min‐1 during pause)
Number of subjects: 0
Study 9138869 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin injections (3 doses of 3.6 mg subcutaneously at 4-week intervals) followed by hysteroscopic resection if fibroids remained submucous.
Number of subjects: 100
Study 9138869 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal uterine cavity.
Number of subjects: 100
Study 30019265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) programme, 4 months of weekly classes of 45 min
Number of subjects: 186
Study 30019265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) programme
Number of subjects: 186
Study 30019265 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle activity (Control)
Number of subjects: 186
Study 27965257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab 150 mg
Number of subjects: 371
Study 27965257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab 75 mg
Number of subjects: 371
Study 27965257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 27965257 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (combined groups)
Number of subjects: 371
Study 25877278 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Reappraisal Coping Intervention (PRCI)
Number of subjects: 50
Study 25877278 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 50
Study 23516997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery-oriented climate
Number of subjects: 108
Study 23516997 — intervention group
Group type: COMPARATOR
Intervention: Performance-oriented climate
Number of subjects: 108
Study 21328040 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivor Health and Resilience Education Program (SHARE) intervention
Number of subjects: 75
Study 21328040 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 75
Study 19223739 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection NK
Number of subjects: 0
Study 19223739 — intervention group
Group type: COMPARATOR
Intervention: Taxol injection
Number of subjects: 0
Study 16603828 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 12622764 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (rabeprazole 20 mg b.d., rifabutin 300 mg once daily, levofloxacin 500 mg once daily for 7 days)
Number of subjects: 109
Study 12622764 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy (rabeprazole 20 mg b.d., metronidazole 400 mg t.d.s., bismuth subcitrate 120 mg q.d.s., tetracycline 500 mg q.d.s. for 7 days)
Number of subjects: 109
Study 12622764 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 109
Study 12622764 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy
Number of subjects: 109
Study 10833553 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg daily)
Number of subjects: 40
Study 10833553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9339085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises with urethral biofeedback for 8 weeks
Number of subjects: 39
Study 9339085 — intervention group
Group type: COMPARATOR
Intervention: Pelvic muscle exercises alone
Number of subjects: 39
Study 8411891 — intervention group
Group type: EXPERIMENTAL
Intervention: ICCE with ACL
Number of subjects: 360
Study 8411891 — intervention group
Group type: COMPARATOR
Intervention: ECCE with PCL
Number of subjects: 360
Study 8411891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 360
Study 3513720 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 58
Study 3513720 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 28716428 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin treatment (40mg atorvastatin)
Number of subjects: 2000
Study 28716428 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity statin treatment (20mg pravastatin)
Number of subjects: 2000
Study 26928074 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with aluminum hydroxide
Number of subjects: 678
Study 26928074 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with MF59(®)
Number of subjects: 678
Study 26928074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study 24907703 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLE model presentations
Number of subjects: 0
Study 24907703 — intervention group
Group type: COMPARATOR
Intervention: Control group presentations
Number of subjects: 0
Study 22264496 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview for Deterioration in Daily Living Activities in Dementia (IDDD)
Number of subjects: 301
Study 20359934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (500 units)
Number of subjects: 116
Study 20359934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 18555114 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker verapamil (100 microg injected into renal artery)
Number of subjects: 96
Study 18555114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no verapamil)
Number of subjects: 96
Study 16133638 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk Basic Protein (MBP) 40 mg per day for 6 months
Number of subjects: 32
Study 16133638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16133638 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk Basic Protein (MBP)
Number of subjects: 32
Study 12234091 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced therapy (mCIT)
Number of subjects: 14
Study 12234091 — intervention group
Group type: COMPARATOR
Intervention: regular therapy (TR)
Number of subjects: 14
Study 12234091 — intervention group
Group type: COMPARATOR
Intervention: no therapy (CON)
Number of subjects: 14
Study 10196785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage surgical procedure and immediate loading (Experimental Group - EG)
Number of subjects: 27
Study 10196785 — intervention group
Group type: COMPARATOR
Intervention: 2-stage surgical procedure (Reference Group - RG)
Number of subjects: 27
Study 10196785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EG and RG)
Number of subjects: 27
Study 7495630 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite inlays
Number of subjects: 142
Study 7495630 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite restorations
Number of subjects: 142
Study 2334030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnanolone emulsion
Number of subjects: 6
Study 2334030 — intervention group
Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 6
Study 291771 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ZAPO induction program (daunomycin, 5-azacytidine, cytosine arabinoside, prednisone, and vincristine)
Number of subjects: 163
Study 291771 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy (BCG and allogenic acute myelomonocytic leukemic cells)
Number of subjects: 163
Study 291771 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 163
Study 31575574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 2346
Study 31575574 — intervention group
Group type: COMPARATOR
Intervention: Conventional in vitro fertilisation (IVF)
Number of subjects: 2346
Study 29202867 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Rs and 2Ss Multiple Family Group (MFG) intervention
Number of subjects: 2688
Study 29202867 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic Implementation Team (CIT) adaptation
Number of subjects: 2688
Study 26452709 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 units subcutaneously once per week for a maximum of three doses)
Number of subjects: 606
Study 26452709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride subcutaneously once per week for a maximum of three doses)
Number of subjects: 606
Study 26452709 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 606
Study 26452709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 24460808 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ECG monitoring during standing response
Number of subjects: 40
Study 24460808 — intervention group
Group type: COMPARATOR
Intervention: Brisk supine to standing response
Number of subjects: 40
Study 22924372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplements (1 gr daily for three months)
Number of subjects: 90
Study 22924372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19180855 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension seat
Number of subjects: 12
Study 19180855 — intervention group
Group type: COMPARATOR
Intervention: Fixed seat
Number of subjects: 12
Study 17718695 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of antiepileptic drugs (AEDs)
Number of subjects: 39
Study 15249567 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 mg once daily (plus stavudine placebo twice daily) (n = 286)
Number of subjects: 571
Study 15249567 — intervention group
Group type: COMPARATOR
Intervention: Stavudine at standard doses twice daily (plus emtricitabine placebo once daily) (n = 285)
Number of subjects: 571
Study 15249567 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine group
Number of subjects: 571
Study 15249567 — intervention group
Group type: COMPARATOR
Intervention: Stavudine group
Number of subjects: 571
Study 11573924 — intervention group
Group type: EXPERIMENTAL
Intervention: DonJoy Legend brace
Number of subjects: 31
Study 11573924 — intervention group
Group type: COMPARATOR
Intervention: Mechanical placebo brace
Number of subjects: 31
Study 11573924 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 31
Study 11573924 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (DonJoy Legend brace, Mechanical placebo brace, No brace)
Number of subjects: 31
Study 9363379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat exercise (LFEX)
Number of subjects: 21
Study 9363379 — intervention group
Group type: COMPARATOR
Intervention: Low fat control (LFC)
Number of subjects: 21
Study 8317714 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive needle polarity
Number of subjects: 10
Study 8317714 — intervention group
Group type: COMPARATOR
Intervention: Negative needle polarity
Number of subjects: 10
Study 8317714 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of mean ratio of positive to negative threshold stimulation current
Number of subjects: 10
Study 3551551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg for 7 nights
Number of subjects: 62